Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

repeatedly over nearly eight years to obtain a broader scope, but the USPTO rejected all of those attempts because multiple other researchers (including Dr. Liau and NW Bio) had already used dendritic cell treatments in a wide variety of sequences and timings with chemotherapies years before the Cedars Sinai/IMUC patent application was filed.  

Simply stated, NW Bio's DCVax product and treatment regimen do not fall within the narrow sequence and timing covered by the '090 patent.  The purpose and focus of NW Bio's clinical trials is to prove that DCVax is an effective treatment on its own.  Moreover, when NW Bio's DCVax reaches commercialization, the treating physician, not NW Bio, will be the party who administers DCVax, and who determines what further treatment to use in the event of recurrence.  NW Bio does not advise on post-recurrence therapies other than the use of its vaccine.  It is the physician who will determine whether to administer chemotherapy and, if so, which type of chemotherapy and in what manner. 

Additionally, all of these treatment activities can be undertaken by the physician free of the '090 patent in a variety of ways.  For example, step (b) of the patent was narrowed following USPTO rejections so as to include only the specific drugs listed. This list does not include the chemotherapy that doctors usually prescribe today after glioma recurrence (Avastin). 

  • The '090 patent is not applicable to treatment for most types of cancer.

Cedars Sinai/IMUC application sought a patent for "treating a disease condition in a mammal" but this was rejected by the USPTO.  Indeed, the USPTO would not even allow coverage of all cancers, or even all cancers of the central nervous system.  The patent claim was narrowed to just "treating a glioma in a mammal."  Glioma is only one of multiple sub-types of one cancer:  pr
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Santa Paula, CA (PRWEB) September 15, 2014 ... of long term implantable silicones for the medical ... strength, responsive silicone gel for the implantable medical ... incorporates a unique crosslink technology delivering a silicone ... adhesion. The Dual Matrix technology consists of ...
(Date:9/15/2014)... September 15, 2014 Hydro Dynamics, ... announced today that it will be partnering with ... ( http://www.proteaf.com ) for implementing its Shock Wave ... continuous processing. Continuous flow chemistry through process ... pharmaceutical and petrochemical markets for decades. The ...
(Date:9/12/2014)... magnet using an electric field (magnetoelectric memory [MEM] ... next-generation technology for information processing and storage. Multiferroic ... due to the coexistence of electric and magnetic ... spontaneous electric and magnetic polarizations is rare in ... the MEM effect. This article briefly reviews a ...
(Date:9/12/2014)... -- On Thursday, September 11, 2014, the NASDAQ ... Average finished the day 0.12% lower at 17,049.00, and the ... broad based as seven out of ten sectors ended the ... ended the day at 741.83, down 0.33%, while the index ... initiated coverage on the following equities: Exelixis Inc. (NASDAQ: ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5
... Oct. 31, 2011 Reportlinker.com announces that ... in its catalogue: US ... http://www.reportlinker.com/p0397796/US-Intranasal-Drug-Delivery-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology This report ... Delivery in US$ Million by the following ...
... iBio, Inc. (NYSE AMEX: IBIO ) ... Patent and Trademark Office for US Patent 8,058,511, entitled ... extends iBio,s patent coverage of viral vectors comprising its ... developed by scientists at iBio,s research collaborator, the Fraunhofer ...
... BETHESDA, Md., Oct. 28, 2011 , ... innovator in biotechnology for therapy in diabetes, metabolic syndrome ... services to food, supplement, biotechnology and pharmaceutical companies – ... sell $1.25 million of shares of its common stock ...
Cached Biology Technology:US Intranasal Drug Delivery Industry 2US Intranasal Drug Delivery Industry 3US Intranasal Drug Delivery Industry 4US Intranasal Drug Delivery Industry 5US Intranasal Drug Delivery Industry 6US Intranasal Drug Delivery Industry 7US Intranasal Drug Delivery Industry 8US Intranasal Drug Delivery Industry 9US Intranasal Drug Delivery Industry 10iBio Announces New US Patent for iBioLaunchâ„¢ Technology 2iBio Announces New US Patent for iBioLaunchâ„¢ Technology 3Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 2Spherix Announces Closing of Private Placement of $1.25 Million, Discusses Use of Proceeds 3
(Date:9/15/2014)... carbon-halogen bonds are produced naturally across all kingdoms of ... with a broad range of biological activities. The presence ... profound influence on their molecular properties. , ... been to find the late-stage, site-specific incorporation of a ... an sp C-H bond (one of the most inert ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Research suggests that genes that affect hearing and cognitive ... the ability to understand and perceive rhythm, pitch, timbre, ... authors of a BioEssays article explain that ... within a population, with the majority of individuals having ... a complex trait attributable to several underlying genes, and ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... about Arctic climate variation during an ancient episode of ... climate variability in the greenhouse world of the Late ... probably would not greatly change the climatic influence associated ... the El Nio Southern Oscillation (ENSO) or ...
... Springer journals Frontiers of Medicine and Protein ... important literature database for medical and biomedical articles, in January. ... publishing partner Higher Education Press. Both journals are part of ... 90 Springer journals. Frontiers in Medicine has a ...
... Ancient stone faces carved into the walls of a well-known ... searching for fossils of extinct giant rats., The team of archaeologists ... tip of East Timor. "Looking up from the cave floor ... on what seemed to be a weathered carving," CSIRO,s Dr Ken ...
Cached Biology News:Arctic climate variation under ancient greenhouse conditions 2Arctic climate variation under ancient greenhouse conditions 3Research literature from China listed in Medline 2Giant rats lead scientists to ancient face carvings 2
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: